EXACTLY. Hence they should have used the word 'EFFICACY' in the PR headline as well as in the body of the PR within the context of leronlimab working and not as a decriptor of endpoints.

Those thumbs downing me about this should recognize that the market is aware of this (SP is down) so there's no benefit to burying your head in the sand about it.